NEW YORK, November 14, 2017 /PRNewswire/ —
Q BioMed Inc. (OTCQB: QBIO) congratulates our collaborative research partner and licensor, Mannin Research Inc., on receiving R&D funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to initiate work on a Tie2-activating biologic for the treatment of glaucoma. Q BioMed has licensed the Mannin Tie2 technology, and is collaboratively developing the Tie2 platform for glaucoma, and other indications. This new biologic would be an additional product to the Mannin Tie2 pipeline.
Mannin’s new biologic therapeutic was developed by Mannin’s CSO, Dr. Susan Quaggin and her laboratory. The biologic has the potential to treat several additional, vascular related diseases, such as acute kidney injury, and cardiorenal syndrome. “As our understanding about the Angiopoietin-Tie2 system grows, I am very excited about the clinical therapeutic possibilities,” said Dr. Quaggin.
In the project, Mannin research will conduct a proof-of-concept study to determine the efficacy of its novel, specific, and potent biologic therapeutic. The research is supported by the NRC IRAP and will assist in Mannin developing additional research capacity within Mannin.
The impact of novel therapeutics developed by Mannin has direct benefits to Canadian glaucoma patients and those suffering with glaucoma around the world. There is an acute need for better therapeutic solutions for the hundreds of thousands of people suffering from glaucoma and those yet to be diagnosed. The number of potential patients in this therapeutic area demanding better treatments make this a multi-billion-dollar opportunity.
It is anticipated, success in the biologic proof-of-concept project will enable Mannin to add to its R&D pipeline. Development of the MAN-01 small molecule for the treatment of primary open-angle glaucoma continues on-pace and is now at a point where the most active candidates will be selected for final testing and optimization as a soluble, topical eye drop that permeates well into the eye. It is anticipated that pre-clinical IND enabling studies will begin in Q2 2018.
About Mannin Inc.
Mannin Research Inc is utilizing a proprietary research platform, this technology is addressing the need for a new class of drugs to treat various vascular diseases. Our lead indication is for a First-In-Class therapeutic eye drop for the treatment of Primary Open Angle Glaucoma. Mannin is developing a unique molecule in the form of an easy to administer eye drop designed to repair the normal flow of fluid in the eye resulting in the reduction of intra-ocular eye pressure (IOP), one of the main causes of Glaucoma. Mannin is the only company targeting this method of action. Mannin has a deep pipeline of novel therapeutics that can be developed from this research platform, which would treat a spectrum of vascular diseases including Cystic Kidney Disease, Pediatric Glaucoma, Cardiovascular Disease and Inflammation.
About Q BioMed Inc.
Q BioMed Inc. “Q” is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need.
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Q BioMed Inc.
SOURCE Q BioMed Inc.